Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,961 people get BSX articles and Market Currents by email alert.

Get email alerts on BSX »

BSX

Boston Scientific Corporation

5/18/2013, 4:20 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 3:44 PM Boston Scientific (BSX +4.4%) is set to finish strong today after announcing earlier that it's first patient has been enrolled in a clinical investigation evaluating the use of its WallFlex Biliary RX Stent, a self-expanding metal stent used as a bridge to surgery. The study is expected to enroll 294 patients at leading hospitals in Australia, Belgium, Canada, France, Hong Kong, India, Italy and Japan. Comment! [Healthcare, On the Move]
Friday, May 10, 4:33 PM Medtronic (MDT) says data presented at the Heart Rhythm Society's 34th Annual Scientific Sessions show its Lead Integrity Alert software detected pace/sense lead issues in non-MDT leads at a greater rate than standard impedance monitoring alone. The analysis, which focused on BSX's Endotak leads, shows that for every one Endotak pace/sense lead issue detected by impedance monitoring, the LIA software detected four cases that were missed. Comment! [Healthcare]
Thursday, May 9, 2:12 PM Boston Scientific (BSX +5%) hits a new 52-week high after reporting follow-up data from its Protect AF clinical trial demonstrating that its Watchman Left Atrial Appendage Closure device was statistically superior to Bristol-Myers (BMY) Warfarin in preventing cardiovascular death, strokes and systemic embolization. 1 Comment [Healthcare, On the Move]
Friday, April 26, 2:48 PM Boston Scientific (BSX -1.6%) gives back a pre-market pop plus more today, despite being upped to Outperform at Credit Suisse with a price target of $8.75. The firm says the company is on track for the first time in years to post positive sales growth, and that management's "continued commitment to returning to positive sales growth H213 & to improving margins despite a tough pricing environment" is encouraging. Comment! [Healthcare, On the Move]
Thursday, April 25, 10:05 AM More on Boston Scientific (BSX +1.2%) Q1: swings to net loss of $354M from a profit of $113M a year earlier after taking charges of $578M for litigation and restructuring expenses. Sales breakdown: cardiovascular +12%, rhythm management -5%, MedSurg sales +2%. Expects Q2 adjusted EPS of $0.14-0.17 vs consensus of $0.10, and revenue of $1.74-1.8B vs $1.81B; Revises FY guidance: now expects EPS of $0.65-0.70 vs prior outlook of $0.64-0.70 and consensus of $0.41; and revenues of $6.95-7.15B vs $7.05-7.35B prior and expectations of $7.18B. (PR) Comment! [Healthcare, Earnings]
Thursday, April 25, 7:04 AM Boston Scientific (BSX): Q1 EPS of $0.16 beats by $0.07. Revenue of $1.76B (-6% Y/Y) misses by $0.03B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Friday, April 12, 3:48 PM Boston Scientific (BSX +0.4%) says it's received FDA approval for its Precision Spectra Spinal Cord Stimulator System. The system, which will be launch on a limited basis in the U.S., uses Illumina 3D software and 32 contacts and is designed to provide improved pain relief to patients who suffer from chronic pain. Comment! [Healthcare]
Thursday, April 11, 4:16 PM Shares of Boston Scientific (BSX -1.5%) tanked into the close of trading today, with no significant news hitting the tape. Comment! [Healthcare, On the Move]
Wednesday, April 3, 2:45 PM Boston Scientific (BSX -2.2%) dips after Credit Suisse analyst Bruce Nudell cut the shares from Outperform to Neutral on valuation earlier today. In his report, Nudell notes that while he doesn't see its current valuation as overstretched, the shares are now within 8% of his target price and with elevated expectations from the Street already priced in, the stock no longer has enough upside to warrant the higher rating. Comment! [Healthcare, On the Move]
Sunday, March 10, 3:48 AM A study has found that Boston Scientific's (BSX) Watchman device for preventing strokes, blood clots and heart-related deaths in patients with atrial fibrillation was safer than thought in a previous trial. However, the product wasn't more effective than the blood thinner warfarin. Notwithstanding, Boston plans to file for FDA approval, although one cardiologist is skeptical, due to the relatively small size and length of the latest study. (PR) 2 Comments [Healthcare]
Friday, March 8, 11:03 AM Boston Scientific (BSX +0.5%) gets slapped with a patent infringement lawsuit in Ireland filed by Orbus International, a subsidiary of OrbusNeich Medical. The lawsuit contends that BSX's coronary stent systems, including the Promus Element, Promus Element Plus, Omega, Taxus, Synergy, and Promus Premier lines of stents, infringe on two of OrbusNeich's European patents covering certain novel stent designs. OrbusNeich is seeking damages and an injunction prohibiting BSX from manufacturing, offering for sale, marketing or stocking products that infringe on the patents in Ireland. Comment! [Healthcare, Global & FX]
Tuesday, February 26, 10:03 AM The award of $3.35M against J&J (JNJ +0.8%) over its vaginal mesh in a case involving a South Dakota patient could have an impact on other suits against the company and rival manufacturers C.R. Bard (BCR +0.3%), Boston Scientific (BSX -0.3%) and Endo Health (ENDP +0.3%). Around 11,000 claims have been consolidated into five cases that are pending in West Virginia. Comment! [Healthcare]
Tuesday, February 12, 2:57 PM Boston Scientific (BSX -0.5%) slips into the red today, despite saying it's received CE Mark approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, and is initiating its European market launch. The system is designed to provide physicians improved drug eluting stent performance for treating patients with coronary artery disease. 2 Comments [Healthcare, Global & FX]
Thursday, January 31, 4:09 PM Despite the marketshare gains Cardiovascular Systems (CSII) has made with its Diamondback and Stealth devices for treating narrowed or blocked arteries in the leg, the real value in the company may lie in its takeout potential, says Seeking Alpha contributor Stephen Simpson. CR Bard, Cook, BSX, JNJ, MDT and ABT all have sales forces in the peripheral treatment space, making them solid candidates for a possible buyout of CSII. Comment! [Healthcare, M&A]

1
2
3
4
5
6
...
11
Next Page